Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%0.00%0.00%0.00%+241.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%0.00%0.00%0.00%+241.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$10.25M1.85N/AN/A$4.74 per share2.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$5.35M-$2.07N/AN/AN/A-36.23%-101.40%-31.86%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.271.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AInsider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.72 million1.68 millionNot OptionableEVOK, JPJ, RNK, and 888 HeadlinesRecent News About These CompaniesWilliam Hill owner Evoke in talks with Ball's Intralot about potential takeoverApril 20, 2026 | proactiveinvestors.co.ukWilliam Hill UK owner Evoke confirms $304 million takeover bid from Bally's IntralotApril 20, 2026 | reuters.comWilliam Hill owner Evoke reports strongest quarter of the year, sale process ongoingJanuary 27, 2026 | proactiveinvestors.co.ukDeutsche Bank downgrades Evoke and Rank as gaming outlook resetsJanuary 23, 2026 | proactiveinvestors.co.ukQOL Medical, LLC: Evoke Pharma and QOL Medical Announce Expiration of Tender OfferDecember 17, 2025 | finanznachrichten.deEvoke Pharma and QOL Medical Announce Expiration of Tender OfferDecember 17, 2025 | prnewswire.comWilliam Hill owner Evoke puts business up for sale as gambling taxes weighDecember 10, 2025 | proactiveinvestors.co.ukHalper Sadeh LLC Encourages EVOK, FSFG, BRY Shareholders to Contact the Firm to Discuss Their RightsDecember 2, 2025 | caledonianrecord.comCEntain, Evoke and Flutter warn of jobs cuts and illegal gambling due to Budget tax hikeNovember 27, 2025 | proactiveinvestors.co.ukEvoke assesses Italian unit sale amid tax concerns ahead of budget, Sky News reportsNovember 25, 2025 | reuters.comNovo Nordisk evoke Phase III trial miss in Alzheimer's diseaseNovember 25, 2025 | thepharmaletter.comTGLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide missNovember 24, 2025 | msn.comEvoke Pharma Announces Merger with QOL MedicalNovember 10, 2025 | theglobeandmail.comEvoke Pharma (NASDAQ:EVOK) Major Shareholder Sells $95,850.00 in StockNovember 8, 2025 | insidertrades.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Evoke Pharma,November 4, 2025 | caledonianrecord.comC$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Evoke Pharma, Inc. (NASDAQ: EVOK)November 4, 2025 | globenewswire.comShareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public ShareholdersNovember 4, 2025 | prnewswire.comEVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to ShareholdersNovember 4, 2025 | businesswire.comEvoke Pharma stock soars after QOL Medical acquisition announcementNovember 4, 2025 | za.investing.comEvoke Pharma Enters into Definitive Agreement to Be Acquired by QOL MedicalNovember 4, 2025 | markets.businessinsider.comEVOK, JPJ, RNK, and 888 Company DescriptionsEvoke Pharma NASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
